文献速递临床试验与 GCP

UPDATE试验(皮肤病学中窄谱UVB治疗特应性湿疹):窄谱UVB联合最佳局部治疗对比最佳局部治疗治疗特应性湿疹患者的随机对照试验研究方案

The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.
PubMed 文献 · Trials · 2024-07-16

UPDATE试验为实用性、多中心、前瞻性、随机、开放标签、盲法终点(PROBE)试验,计划1:1随机分配316例局部治疗控制不佳的中重度特应性湿疹成人患者,比较最佳局部治疗(OTT)联合窄谱UVB(NB-UVB)与单用OTT的短期和长期(成本)效果及安全性。干预组接受至少3个月OTT联合8至16周NB-UVB,对照组接受3个月OTT,随后随访9个月。

要点

  • NB-UVB光疗常用于中重度特应性湿疹,但当前证据确定性低,疗效尚未充分确立。
  • UPDATE试验采用PROBE设计,1:1随机分配316例成人患者,比较OTT联合NB-UVB与单用OTT。
  • 干预组接受至少3个月OTT联合8至16周NB-UVB,对照组接受3个月OTT,随后随访9个月。

核心结论

  • UPDATE试验旨在为中重度特应性湿疹成人患者中NB-UVB光疗的(成本)效果和安全性提供高质量证据。

研究设计与样本

  • 实用性、多中心、前瞻性、随机、开放标签、盲法终点(PROBE)试验,1:1随机分配316例局部治疗控制不佳且适合下一步接受OTT或NB-UVB联合OTT的中重度特应性湿疹成人患者。

主要发现

  • 干预组接受至少3个月OTT联合8至16周NB-UVB,对照组接受3个月OTT,干预阶段后随访9个月。
  • 根据湿疹协调结局指标(HOME)核心结局集,在4周、3、6、9和12个月评估医生报告和患者报告的结局及不良事件。

关键数值与推荐

  • 干预组NB-UVB治疗持续8至16周,联合OTT至少3个月;对照组OTT持续3个月。
  • 结局评估时间点为4周、3、6、9和12个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 方案中提及的挑战包括开放标签治疗可能带来的偏倚,以及为预防高脱落率而必须在研究设计中引入OTT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, as current evidence is of low certainty. Our aim is to assess the short-term and long-term (cost-)effectiveness and safety of NB-UVB in adult AE patients by performing a pragmatic, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial. This protocol outlines its methodology. METHODS: A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eligible for optimal topical therapy (OTT) or NB-UVB in combination with OTT as a next step. Participants in the interventional arm will receive a minimum of 3 months of OTT combined with 8 to 16 weeks of NB-UVB. The control group receives 3 months of OTT. Following the interventional phase, follow-up will continue for 9 months. Physician-reported and patient-reported outcomes (according to the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set) and adverse events are assessed at 4 weeks, 3, 6, 9, and 12 months. DISCUSSION: The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the protocol include the possible bias arising from applying open-label treatment and the necessity of introducing OTT into the study design to prevent a high dropout rate. TRIAL REGISTRATION: ClinicalTrials.gov NCT05704205. Registered on December 8, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Knöps E, Spuls P, Duijnhoven R, et al. The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema. Trials. 2024. PMID: 39014498. doi:10.1186/s13063-024-08334-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。